Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors or Recurrent Glioblastoma

NCT02895360 is registered in ClinicalTrials.gov with Basilea Pharmaceutica as lead sponsor.

NCT NCT02895360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02895360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors or Recurrent Glioblastoma
Lead sponsor
Basilea Pharmaceutica
Phase
Phase 1/2
Overall status
Completed
Start date
August 24, 2016
Completion date
August 7, 2020
Enrollment
43 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms